Categories
- PROTAC Linker
- Protein Control Ligand
- Pathway Inhibitors
- Function Modulators
- Activators
- G Protein-Coupled Receptor Ligands
- Nuclear Receptor Ligands
- GDNF Receptors
- TNF Receptors
- Transcription Factors
- Chemokines
- Cytokine Receptors
- Biomarkers and Buffer Solutions
- Molecular Probes
- Stem Cell Research
- Alzheimer's Disease
- Apoptosis
- Cancer Research
- Epigenetics
- Metabolites
- PET/SPECT Imaging Precursors
- Customized Screening Library
- Ultra Pure Pharmacological Standard
- Tissue Microarray (TMA)
- Proteins and Antibodies
- Primary Cells
- ELISA KIT
- Natural Products
- Lab Equipments
- Humanized Mice for PDX Platform
- Rare Chemicals
- Custom Synthesis
- Antibacterial
- Antifungal
- Antioxidant
- Antiviral
- Molecular Glues
- SARS-CoV
Quantity Discount Table - Order More To Get More Price Discount
| Quantity | mg | Unit Price ($/mg or $/Unit) | Final Price |
|---|---|---|---|
| 1 | 5 | $34.00 | Total: $170.00 |
| 1 | 10 | $28.80 | Total: $288.00 |
| 1 | 25 | $24.40 | Total: $610.00 |
| 1 | 50 | $20.80 | Total: $1,040.00 |
| 1 | 100 | $18.00 | Total: $1,800.00 |
Overview
JNJ- 10198409 is a relatively selective and ATP competitive PDGF-RTK inhibitor (IC50=2 nM). JNJ-10198409 has good activity against PDGFR-? kinase (IC50=4.2 nM) and PDGFR-? kinase (IC50=45 nM). It is a dual-mechanism, antiangiogenic, and tumor cell antiproliferative agent.
Chemical Properties
| Molecular Formula | C18H16FN3O2 |
| Molecular Weight | 325.34 |
| CAS Numbers | 627518-40-5 |
| Solubility | DMSO |
| Purity | 98% by HPLC |
| SMILES Code | COc1cc2Cc3c(Nc4cccc(F)c4)n[nH]c3-c2cc1OC |
Storage and Handling
0C Short Term, -20C Long Term
References
D'Andrea MR, et al. Validation of in vivo pharmacodynamic activity of a novel PDGF receptor tyrosine kinase inhibitor using immunohistochemistry and quantitative image analysis. Mol Cancer Ther. 2005 Aug;4[8] 1198-204.